Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01154842|
Recruitment Status : Unknown
Verified January 2010 by Diskapi Teaching and Research Hospital.
Recruitment status was: Active, not recruiting
First Posted : July 1, 2010
Last Update Posted : July 14, 2010
|Condition or disease|
Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in dialysis patients, the aim of this study was to test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients.
Methods: In this cross-sectional study, plasma FGF-23 concentrations are measured using a C-terminal human enzyme-linked immunosorbent assay kit and echocardiography is performed in maintenance haemodialysis patients.
Serum FGF-23 levels will be measured in patients with a history of coronary artery disease and aortic valve calcifications.It will be searched whether patients with MPI>0.47 had higher or lower serum FGF-23 levels than those with MPI<0.47. Correlations will be examined between log FGF-23 levels and LVMI and MPI. Uni and Multivariable-adjusted regression analyses regarding whether increased log FGF-23 concentrations are independently associated with increased left ventricular mass index and increased MPI, will be performed.
|Study Type :||Observational|
|Actual Enrollment :||128 participants|
|Official Title:||Serum Fibroblast Growth Factor-23 (FGF-23) Levels Are Independently Associated With Left Ventricular Mass and Myocardial Performance Index in Maintenance Haemodialysis Patients|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||May 2010|
|Estimated Study Completion Date :||June 2010|
Adult hemodialysis patients (age>18 years)
- To test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients. [ Time Frame: 7 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01154842
|Diskapi Training and Research Hospital|
|Study Chair:||ALPER KIRKPANTUR, Assoc Prof||Diskapi Training and Research Hospital|
|Study Chair:||MUSTAFA BALCI, Dr||Diskapi Training and Research Hospital|
|Study Chair:||OGUZ GURBUZ, Dr||Diskapi Training and Research Hospital|
|Study Chair:||BARIS AFSAR, Dr||Zonguldak Training and Research Hospital|
|Study Chair:||BASOL CANBAKAN, Assoc Prof||Diskapi Training and Research Hospital|
|Study Chair:||RAMAZAN AKDEMIR, Assoc Prof||Diskapi Training and Research Hospital|
|Study Director:||DENIZ AYLI, Assoc Prof||Diskapi Training and Research Hospital|